DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varaprath, S.
Right arrow Articles by Plotzke, K. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varaprath, S.
Right arrow Articles by Plotzke, K. P.

Vol. 31, Issue 2, 206-214, February 2003

Metabolites of Hexamethyldisiloxane and Decamethylcyclopentasiloxane in Fischer 344 Rat Urine---A Comparison of a Linear and a Cyclic Siloxane

Sudarsanan Varaprath, Joan M. McMahon, and Kathleen P. Plotzke

Dow Corning Corporation, Midland, Michigan

Hexamethyldisiloxane (MM or HMDS) and decamethylcylclopentasiloxane (D5) are examples of a linear and a cyclic siloxane, respectively. These volatile low molecular weight siloxanes are of significant commercial importance. To aid in the pharmacokinetic investigations, major metabolites of MM and D5 were identified in urine collected from Fischer (F-344) rats administered [14C]MM and [14C]D5 orally and via intravenous injection. The metabolite profiles were obtained using a high-pressure liquid chromatography (HPLC) system equipped with a radioisotope detector. The metabolite elution was carried out on a C18 column using an acetonitrile/water mobile phase. The structural assignments were based on GC-MS analysis of the tetrahydrofuran extract of urine containing the metabolites. Some of the metabolites in the extracts were first protected with trimethylsilyl groups prior to GC-MS analysis using bis(trimethylsiloxy)trifluoroacetamide or highly purified hexamethyldisiloxane. The structures were also confirmed by comparisons with synthetic 14C-labeled metabolite standards. The following are among the major metabolites identified in the case of MM: Me2Si(OH)2, HOMe2SiCH2OH, HOCH2Me2SiOSiMe2CH2OH, HOMe2SiOSiMe2CH2-OH, HOCH2Me2SiOSiMe3, and Me3SiOH. The metabolites of D5 are as follows: Me2Si(OH)2, MeSi(OH)3, MeSi(OH)2OSi(OH)3, MeSi(OH)2OSi(OH)2Me, MeSi(OH)2OSi(OH)Me2, Me2Si(OH)OSi(OH)Me2, Me2Si(OH)OSiMe2OSi(OH)Me2, nonamethylcyclopentasiloxanol, and hydroxymethylnonamethylcyclopentasiloxane. No parent MM or D5 was present in urine The presence of certain metabolites such as HOMe2SiCH2OH and Me2Si(OH)2 in MM and D5, respectively, clearly established the occurrence of demethylation at the silicon-methyl bonds. Metabolites of the linear siloxane are structurally different from that obtained for cyclic siloxane except for the commonly present Me2Si(OH)2. Mechanistic pathways for the formation of the metabolites were proposed.


Copyright © 2003 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics.